Twelve Closed Doors and a Promising Dataset: Oregon's Psilocybin Program in 2026

A client of mine recently asked me to help them think through a decision: whether to spend a rent-sized portion of their savings on a single session at a psilocybin service center. We sat with the arithmetic together. On one side, preliminary outcome data, their treatment history, and a hope they'd been carrying for a year. On the other, the grocery budget, the car repair fund, and the fact that there is no refund if a four-figure afternoon doesn't help. That deliberation, benefit probabilities weighed against rent money, is a clinical conversation now. In Portland, it's almost a routine one.

It's also the entire story of Oregon's program in miniature. You've probably seen the national headline version: a third of Oregon's licensed psilocybin service centers have closed. You may not have seen the other headline from the same month: the first outcome data from the program shows clients getting better. Both are accurate. Holding them together, instead of picking the one that fits your priors, is the only way to understand what Oregon is actually teaching the field.

The numbers, per New York Times reporting: twelve Oregon psilocybin service centers closing since early 2024, leaving roughly two dozen operating. NYT reporter Andrew Jacobs's diagnosis was blunt: "It's basically about economics." Annual licensing runs about $10,000 before a center serves a single client. Business insurance prices at roughly three times comparable medical operations. Rents, security requirements, testing, staffing: all of it lands on a revenue base of clients paying entirely out of pocket, typically $1,000 to $3,000 per session, with premium programs well above that. No insurance covers it. Demand at those prices turned out to be smaller than the 2023 gold-rush projections assumed, and the market is correcting the way markets do.

Note what the closure story is not: it is not evidence that supervised psilocybin sessions don't help people. Nothing in a service center's P&L measures that. The closures measure exactly one thing, how many Oregonians can pay four figures cash for a single afternoon of care, and the answer was: fewer than the business plans required.

In February, researchers posted the first outcome data from inside the regulated program: psilocybin sessions delivered under Oregon's model were associated with clinically meaningful improvements in depression, anxiety, and well-being thirty days after the session. The same month, OHSU announced a five-year, $3.3 million award from the National Institute on Drug Abuse, the first federally funded research on legal psychedelic services delivered in community settings, with preliminary data from more than 300 clients and a target of at least 1,600 participants.

Frame this precisely, because overclaiming here would repeat the field's oldest mistake. The February data is a preprint, not yet peer-reviewed. It's observational: no control group, no randomization, a thirty-day window, and clients who self-selected into a four-figure experience, which is its own filter. People who choose and complete psilocybin sessions expecting benefit often report benefit. What the preprint shows is a signal consistent with the clinical trial literature, from the real world rather than the lab. What the NIDA-funded study means is that the federal government now considers that signal worth $3.3 million of serious attention — a quiet landmark for a Schedule I substance being administered legally by non-medical facilitators under state law.

So: preliminary real-world evidence suggests the model helps the people who get through the door. The door is the problem.

Measure 109 built a safety architecture (licensed facilitators, tested products, regulated settings) and left access to the market. The market did what markets do with a high-cost, cash-only service: priced it as a luxury good. Facilitators paid $7,000–$12,000 for state-required training, often on debt, then graduated into a contracting industry where a shrinking number of centers compete for clients who can pay cash. Centers carried day-spa cost structures with pharmaceutical-grade compliance overhead. The people psilocybin research suggests might benefit most, those with treatment-resistant depression, who are disproportionately likely to be poor, rural, or publicly insured, were never going to be the clientele at $3,000 a session.

That's not a personal failure of anyone running a center; most operators I've encountered are mission-driven people doing painful math. It's a structural observation: Oregon ran the experiment of building access on out-of-pocket wellness economics, and the result is now legible. The medicine shows signal. The market model is failing the people the campaign promised to serve. When a treatment works and a delivery system collapses, the lesson is about the delivery system.

There's a comparison worth one paragraph here. New Mexico, whose medical psilocybin program launches in December, wrote a $630,000 treatment equity fund into its state budget, the first state anywhere to fund psilocybin treatment for low-income patients as a design requirement rather than an afterthought. Whatever else happens there, New Mexico looked at Oregon and drew the obvious conclusion: access is a choice you make at the design stage, or a problem you inherit forever after.

If you're a facilitator or considering becoming one: the contraction is real and the honest framing is market correction, not extinction. The centers surviving tend toward two models: genuine low-cost/equity pricing that widens the client pool, or premium positioning with the marketing budget to match. The middle is where the closures live. Watch the regulatory layer too. OPS convened a product potency workgroup this spring to standardize how psilocybin content is calculated and to examine high-psilocin products, a sign the program's clinical infrastructure is still maturing and that staying current is part of the job. And before anyone pays five figures for training in 2026, the arithmetic deserves daylight: count the operating centers, divide by the number of licensed facilitators, and price your debt against that ratio.

If you're a clinician outside Oregon: your state is watching this program and so are your legislators, especially with New Mexico launching and FDA approval of psilocybin plausibly arriving in 2027. The Oregon lesson to carry into those conversations is specific: regulated non-medical psilocybin services can be delivered safely and with apparent benefit, and a program without a financing mechanism is a program for the affluent, with a license structure that slowly starves the people providing the care. Both halves are now demonstrated. The next state, and the post-approval insurance fight, will be decided by which half gets remembered.

My client is still deciding. The data says the session might help; the moderation language matters, and so does the price tag. In 2026, in the state that went first, a clinically promising treatment is being rationed by savings account. That's where things stand, and it is not where they have to stay.

Economics, not clinical failure. About twelve centers have closed since 2024, leaving roughly two dozen. Annual licensing runs about $10,000 before a center serves a client, insurance covers nothing, and sessions cost clients $1,000 to $3,000 out of pocket. Demand at those prices was smaller than 2023 projections assumed, and the market is correcting.

The first real-world data, a February 2026 preprint, found clinically meaningful improvements in depression, anxiety, and well-being thirty days after sessions, and OHSU won a five-year, $3.3 million NIDA award to study the program. But the data is observational, not yet peer-reviewed, with no control group and self-selected clients. It is a promising signal, not proof.

Typically $1,000 to $3,000 per session, paid entirely out of pocket, with premium programs higher. No insurance, public or private, covers it because psilocybin remains federally Schedule I. Facilitators also pay $7,000 to $12,000 for state-required training. Those costs price out the treatment-resistant patients research suggests might benefit most.

That a safety architecture without a financing mechanism becomes a program for the affluent. Oregon built licensed facilitators, tested products, and regulated settings, but left access to the market, which priced sessions as a luxury good. New Mexico drew the lesson and wrote a $630,000 treatment equity fund into its budget as a launch condition.

Peter Addy, PhD, LPC, LMHC is a Portland-based licensed therapist and the founder of Psychedelic Affirming Education, an NBCC-approved continuing education provider for licensed mental health professionals and Oregon Psilocybin Services facilitators. His research background includes work at Yale School of Medicine on psychedelic substances.

Working in or toward Oregon's program? If you're an Oregon clinician or facilitator navigating supervision, scope, or where you fit in this landscape, tell me about it. I supervise and consult on exactly these questions. For everyone else, the PAE newsletter tracks the Oregon data and rulemaking as it develops.